Migraine Prevention with Depakote and Topamax
Current Guideline Positioning
- The American College of Physicians and the Department of Veterans Affairs recommend CGRP monoclonal antibodies and ARBs as first-line agents for migraine prevention, with topiramate and valproate considered second-line agents 1, 2, 3
- The Department of Veterans Affairs and the American College of Physicians provide strong recommendations for CGRP monoclonal antibodies for both episodic and chronic migraine, and for ARBs for episodic migraine 1, 2, 3
- The American College of Physicians and the Department of Veterans Affairs provide weak recommendations for topiramate for prevention of both episodic and chronic migraine, and for valproate for episodic migraine only 1, 2, 3
Efficacy Profile
- Valproate is effective at 500-1500 mg/day (divalproex) or 600-1500 mg/day (sodium valproate) for episodic migraine prevention, with good evidence for efficacy 4, 5, 6, 7
Critical Safety Concerns
- The American Academy of Neurology and the American College of Obstetricians and Gynecologists recommend that valproate should not be used in women of childbearing potential due to known teratogenic effects, particularly neural tube defects 6, 7
- The American Academy of Neurology and the American College of Obstetricians and Gynecologists report additional adverse effects of valproate, including weight gain, hair loss, tremor, liver disease risk, and thrombocytopenia 4, 6, 7
- The American Academy of Neurology reports that topiramate is contraindicated in pregnancy, lactation, nephrolithiasis, and glaucoma, with common adverse effects including paresthesias, cognitive problems, metabolic acidosis, and increased renal stone risk 6, 7